Cross-Cultural Psychopharmacology

Introduction to CCP - Global Pill Puzzle

• CCP Defined: Study of ethnic/cultural influences on psychotropic drug response (pharmacokinetics & pharmacodynamics).
• Scope: Examines variations in drug metabolism, efficacy, side effects, and prescribing patterns across diverse populations.
• Indian Context: Vital due to high genetic diversity, dietary variations, traditional medicine use, and cultural factors affecting treatment.
• Global Pill Puzzle: The challenge of optimizing pharmacotherapy for varied global patient groups.

⭐ Polymorphisms in CYP450 enzymes (e.g., CYP2D6, CYP2C19) show marked inter-ethnic differences, impacting metabolism of many psychotropics like SSRIs and tricyclic antidepressants (TCAs).

Pharmacogenomics & PK/PD - Gene-Drug Tango

• Pharmacogenomics (PGx): Gene variations impacting drug efficacy & toxicity.
• Pharmacokinetics (PK) - "Body on Drug":
  • CYP450 Enzymes: Key for drug metabolism.
    • CYP2D6: Metabolizes many TCAs, SSRIs (fluoxetine, paroxetine), antipsychotics (risperidone, haloperidol). Variants cause Poor (PM), Intermediate (IM), Extensive (EM), Ultrarapid (UM) metabolizers.
    • CYP2C19: Metabolizes citalopram, escitalopram, diazepam. CYP2C19*2, *3 (common in Asians) → PMs, ↑ drug levels & risk.
• Pharmacodynamics (PD) - "Drug on Body":
  • SLC6A4 (SERT): Polymorphisms (e.g., 5-HTTLPR) may influence SSRI response.
• Critical Gene-Drug Pairs (Indian Focus):
  • HLA-B*15:02 & Carbamazepine: High risk of Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN). Screening vital in at-risk populations.
  • HLA-A*31:01 & Carbamazepine: Risk of DRESS, other hypersensitivities.

⭐ HLA-B*15:02 allele testing is a key pharmacogenomic test before carbamazepine initiation in many Asian populations to prevent life-threatening Stevens-Johnson Syndrome.

• 📌 HLA-B*15:02: Be 15 (fifteen) Oh-2 (so) careful with Carbamazepine! (Risk of SJS/TEN).

Cultural Factors & Clinical Practice - Mind Matters Medicine

• Illness Beliefs & Help-Seeking:
  • Cultural views on mental illness (stigma, supernatural causes) affect seeking care.
  • Patient's explanatory model vital for rapport and adherence.
• Adherence Influences:
  • Family/community roles in treatment decisions.
  • Concerns about medication (side effects, dependency).
  • Use of traditional remedies (e.g., Ayurvedic) - check interactions.
• Metabolic Considerations:
  • Diet (e.g., spices, vegetarianism) can alter drug metabolism.
  • Pharmacogenomics: CYP2D6/CYP2C19 variants in Indians impact drug response.
• Communication & Presentation:
  • Language, non-verbal cues, somatization (physical symptoms for distress).

  ⭐ Certain Indian populations have higher CYP2C19 poor metabolizer prevalence, affecting SSRI (e.g., escitalopram) and clopidogrel metabolism, often needing dose adjustments.

Drug-Specific Considerations - Ethnic Rx Insights

• Genetic Polymorphisms (CYP450): Key for drug response.
  • CYP2D6: Affects risperidone, TCAs. Indians: ↑ intermediate metabolizers → slower clearance. Start low.
  • CYP2C19: Affects diazepam, citalopram. Indians: ↑ poor metabolizers → ↑ drug levels/side effects.
• Antipsychotics (e.g., Haloperidol, Risperidone):
  • Indians: often need ↓ doses due to ↑ sensitivity/↓ metabolism → ↓ Extrapyramidal Symptoms (EPS) risk.
• Antidepressants (SSRIs, TCAs):
  • Indians: lower starting doses advised due to slower metabolism, ↑ side effect risk.
• Carbamazepine:
  • ⚠️ HLA-B*1502 screening: crucial in some Indian groups pre-treatment to prevent Stevens-Johnson Syndrome (SJS).

⭐ Indian populations often require approximately 20-50% lower doses of olanzapine/risperidone due to CYP1A2/CYP2D6 variations affecting metabolism.

High‑Yield Points - ⚡ Biggest Takeaways

• Genetic polymorphisms (e.g., CYP2D6, CYP2C19) alter drug metabolism across ethnicities, impacting efficacy and side effects.
• East Asians often require lower doses of antipsychotics and antidepressants due to slower metabolism.
• Dietary habits and herbal remedies can cause significant drug interactions.
• Cultural attitudes towards mental illness and medication profoundly affect treatment adherence.
• Varying side effect profiles, like increased Extrapyramidal Symptoms (EPS) risk, are seen in different ethnic groups.
• Pharmacogenomic testing can guide personalized dosing but has variable accessibility and ethnic-specific data limitations.